TRIALSITEIQ PUBLIC FEASIBILITY SCORECARD · GRADE C

NCT05586581: SV2A & TSPO PET Imaging Measures to Reveal Mechanisms of HIV Neuropathogenesis During Antiretroviral Therapy

Sponsor: Yale University · Phase: PHASE1/PHASE2 · Area: INFECTIOUS_VACCINE · Target Enrollment: 70 pts

Competing Trials Overlap

3 Active Trials

Excess Burn Exposure

$7,996,800

Rescue Site Savings

+$5,272,890

Unlock Full NCT05586581 Backup Super-Site Packet ($49 One-Time Pass)

Download the complete list of top-decile low-cannibalization clinical sites, verified Principal Investigator (PI) direct emails/phones, and protocol optimization benchmarks.

Download $49 NCT05586581 Rescue Dossier →